Boehringer Ingelheim agreed to a multi-product deal with Sino Biopharmaceutical for six preclinical assets spanning antibody-drug conjugates and T cell engager programs. The transaction includes $358 million up front for options across the pipeline, with total milestones reported at up to $7 billion. The deal reflects continued interest in emerging modality platforms—especially ADCs and bispecific or TCE approaches—sourced from China-originating innovation. The structure also suggests a staged development and rights acquisition model rather than a single asset buyout. For the biotech ecosystem, the arrangement reinforces how pharma is managing portfolio risk by pairing large upfront option payments with long-dated milestone triggers tied to clinical progress. It also adds to pressure on smaller developers competing for attention in early preclinical categories.